Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nancy Richert

Neuroradiology Bethesda, MD Medical Doctor

NPI 1437341435 CMS profile 631914

National Institute Of Neurologic Disorders And Stroke, Bldg 10, Rm B1n256 Nih, Bethesda, MD 20892

Open in the dashboard

General payments

$27,252

13 records reported · program years 2021–2025

Research payments

$3,374

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$50,000

1 holding reported · through program year 2025

Through program year 2025, Nancy Richert of Bethesda, MD is reported in the CMS Open Payments database as having received $27,252 across 13 general payments and $3,374 in research payments paid to them. They also declared ownership or investment interests valued at $50,000 across 1 holding.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Neuroradiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,873 2
2025 Research $1,974 1
2024 General $11,642 6
2023 General $9,105 4
2023 Research $1,400 1
2021 General $633 1
2019 Ownership $50,000 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nancy Richert
  • Neuroradiology median
  • Middle half of Neuroradiology
  • National median

In program year 2025, general payments to Nancy Richert were reported at $5,873. Among 399 Neuroradiology profiles paid that year, the median was $279 and the middle half received between $65 and $2,205.

Show as a table
Year Nancy Richert Neuroradiology median Middle half National median
2019 $0 $288 $71–$2,035 $163
2020 $0 $165 $32–$1,794 $114
2021 $633 $238 $42–$1,807 $132
2022 $0 $191 $49–$1,388 $149
2023 $9,105 $228 $56–$1,148 $160
2024 $11,642 $241 $97–$2,192 $164
2025 $5,873 $279 $65–$2,205 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. F. Hoffmann-La Roche AG $21,456 10 payments
  2. E.R. Squibb & Sons, L.L.C. $4,963 1 payment
  3. Genzyme Corporation $633 1 payment
  4. Blueprint Medicines Corporation $200 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $27,252 13 payments
Products named General payments · program years 2021–2025
  1. OCREVUS $19,744 9 payments
  2. AUBAGIO $633 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. Celgene Corporation $3,374 2 payments

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neuroradiology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record